We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AOP Offers More Evidence for Invalidating Cymbalta Patent
AOP Offers More Evidence for Invalidating Cymbalta Patent
September 29, 2009
Article One Partners (AOP) has uncovered new evidence that can show a patent covering Eli Lilly’s blockbuster depression drug Cymbalta is invalid, the group says.